Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
äŒæ¥ã³ãŒãHROW
äŒç€ŸåHarrow Inc
äžå Žæ¥Feb 08, 2013
æé«çµå¶è²¬ä»»è
ãCEOãMullery (Frank)
åŸæ¥å¡æ°382
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 08
æ¬ç€Ÿæåšå°1A Burton Hills Blvd
éœåžNASHVILLE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·37215
é»è©±çªå·16157334731
ãŠã§ããµã€ãhttps://www.harrow.com/
äŒæ¥ã³ãŒãHROW
äžå Žæ¥Feb 08, 2013
æé«çµå¶è²¬ä»»è
ãCEOãMullery (Frank)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã